New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
08:10 EDTLJPCLa Jolla Pharmaceutical, GW University enter into agreement related to LJPC-501
La Jolla Pharmaceutical announced that it has signed an option agreement with the George Washington University that will add proprietary technology to the company’s LJPC-501 program. The option agreement with GW adds potential proprietary protection to La Jolla’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:06 EDTLJPCLa Jolla weakness related to Galectin is overdone, says Wedbush
Subscribe for More Information
10:39 EDTLJPCGalectin drug showed no difference from placebo, The Street reports
Subscribe for More Information
July 23, 2014
09:02 EDTLJPCLa Jolla 4.8M share Spot Secondary priced at $10.50
The deal range was $10.40-$10.60. Jefferies acted as sole book running manager for the offering.
July 22, 2014
16:01 EDTLJPCLa Jolla files to sell common stock, no amount given
La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes. Jefferies LLC is acting as sole book-runner for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use